Blog

Revenue increased 67% y/y to $17.1M with Positive Adjusted EBITDA¹ for Ninth Consecutive Quarter

Adjusted EBITDA¹ increased 387% y/y to $2.9M or 17% of revenue

Net Profit for the quarter of $0.9M and EPS of $0.02

Reaffirms Fiscal 2025 Revenue Guidance Exceeding $60M, Driven by Strong Order Pipeline

TORONTO, ONTARIO / ACCESS Newswire / August 13, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company”) (Nasdaq:ELVA)(TSX:ELVA), a leading lithium-ion battery technology and manufacturing company, today reported its financial results for the third quarter of the fiscal year ending September 30, 2025 (“Q3 2025”). All dollar amounts are in U.S. dollars unless otherwise noted.

Financial Highlights:

• Revenue for Q3 2025 was $17.1 million, compared to $10.3 million in Q3 2024, an increase of 67%. Year to date revenue was $43.3 million compared to $33.0 million in the prior year, an increase of 31%

• Gross margin was 30.8% in Q3 2025. Battery system margins remained strong at 30.9% for the quarter.

• Adjusted EBITDA¹ was $2.9 million or 17% of revenue with growth of 387% year over year.

• Net profit for the quarter was $0.9 million, compared to a net loss in the prior year of $0.3 million. Year to date net profit was $1.3 million compared to a net loss of $1.4 million in the prior year.

• Earnings per share for the quarter was $0.02.

Key Operational and Strategic Highlights – Q3 2025

• Continued Growth from OEM Partners and Leading End-Customers: Electrovaya maintained strong momentum with its key OEM partners and end customers in the material handling sector. In Q3, the Company secured more than $21 million in orders, bringing total orders to over $66 million in the nine months ending June 30th 2025. The Company continues to expand its robust sales pipeline, leveraging long-standing relationships with major OEMs and top-tier end customers.

• Expanded Manufacturing Capacity and Output: To meet growing demand, Electrovaya implemented a second production shift at its Mississauga facility in mid-June and commenced assembly operations in Jamestown, NY in May. These initiatives will increase output for material handling battery systems and support the launch of new products for additional vertical markets

• Infinity Technology Advancements: The Company continued to enhance its Infinity product line, achieving UL certification for more than 400 battery systems equipped with its latest high-capacity lithium-ion cells. New models feature improved ergonomics and AI-enabled capabilities, further strengthening Electrovaya’s competitive edge.

• Development of New Products for Emerging Verticals: Electrovaya is leveraging its industry-leading Infinity technology to expand into a broader range of high-growth applications, including:

  • Robots and Autonomous Vehicles: The Company has introduced multiple battery system products for new robotic vehicle platforms across three distinct OEM customers. Applications range from material handling to surveillance systems. This initiative is part of a major product development program aimed at capturing share in the rapidly growing robotics market.

  • Airport Ground Equipment: Recently, Electrovaya launched products targeting the airport ground support segment and plans to showcase these solutions at the upcoming GSE Expo in Las Vegas this September.

  • Class 8 Trucks: As one of the largest potential markets for electrification, this segment represents a significant growth opportunity. Electrovaya has entered into a partnership with Janus Electric Holdings Limited, an Australian pioneer in heavy-vehicle electrification. The Company is developing custom high-voltage battery systems for a unique battery-swapping application in both U.S. and Australian markets.

  • Construction and Mining Equipment: Through its partnership with Sumitomo Corporation Power and Mobility, Electrovaya is pursuing opportunities with multiple Japan-based OEMs in these sectors.

  • Defense Applications: The Company continues to expand its collaboration with a global defense contractor on various electrification projects. With its superior safety and cycle life advantages, combined with upcoming U.S.-based lithium-ion battery manufacturing, Electrovaya is positioned to target the defense sector on a larger scale in the near term.

• Jamestown Cell Manufacturing Update: The Company remains on track for start of cell manufacturing in mid calendar year 2026. Output from the Jamestown facility will remain eligible for 45X under the OBBB Act (2025).

Management Commentary:

“Our Q3 FY2025 results reflect the strong momentum we’ve built, with continued growth in both revenue and profitability, while advancing our industry-leading Infinity technology into a broader range of applications,” said Dr. Raj DasGupta, Electrovaya’s CEO. “The market is increasingly recognizing the exceptional advantages of our innovations. Electrovaya’s unique lithium-ion technology delivers the ideal solution for the most demanding equipment in the world. With the rise of AI and rapid expansion across sectors like e-commerce and robotics, we are well-positioned to provide superior battery solutions that power these high-growth industries.”

“FY Q3 2025 quarter was our ninth consecutive quarter of positive adjusted EBITDA¹ and also our second consecutive quarterly net profit. Margins remained robust at above 30%, a trend that we expect to continue and strengthen over time.,” stated John Gibson, Electrovaya’s CFO. “Our second shift at our Mississauga operations, combined with the start up of assembly operations in Jamestown will continue to support increased manufacturing output as we complete our fiscal year and prepare for FY2026. We are confident in our ability to exceed $60 million in revenue for FY 2025 while advancing profitability and scaling operations.”

Positive Financial Outlook & Fiscal 2025 Guidance:

The Company anticipates strong growth into FY 2025 with estimated revenues to exceed $60 million driven by renewed demand from the Company’s largest end users of material handling batteries. This guidance considers its existing purchase orders, along with anticipated orders in its pipeline from key end users and customers. This guidance also takes into consideration a percentage of anticipated revenue that may be deferred to FY 2026 (please see Forward Looking Statements for further clarification).

Selected Financial Information for the quarters ended June 30, 2025 and 2024:

Results of Operations

(Expressed in thousands of U.S. dollars)

Adjusted EBITDA¹

(Expressed in thousands of U.S. dollars)

¹ Non-IFRS Measure: Adjusted EBITDA is defined as income/(loss) from operations, plus stock-based compensation costs and depreciation and amortization costs. Adjusted EBITDA does not have a standardized meaning under IFRS. Therefore it is unlikely to be comparable to similar measures presented by other issuers. Management believes that certain investors and analysts use adjusted EBITDA to measure the performance of the business and is an accepted measure of financial performance in our industry. It is not a measure of financial performance under IFRS, and may not be defined and calculated in the same manner by other companies and should not be considered in isolation or as an alternative to IFRS measures. The most directly comparable measure to Adjusted EBITDA calculated in accordance with IFRS is income (loss) from operations.

Summary Financial Position

(Expressed in thousands of U.S. dollars)

The Company’s complete Financial Statements and Management Discussion and Analysis for the quarter and nine months ended June 30, 2025 are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov, as well as on the Company’s website at www.electrovaya.com.

Conference Call details:

• Date: Wednesday, August 13, 2025

• Time: 5:00 pm. Eastern Time (ET)

• Toll Free: 888-506-0062

• International: 973-528-0011

• Participant Access Code: 264442

• Webcast link: https://www.webcaster4.com/Webcast/Page/2975/52770

To help ensure that the conference begins in a timely manner, please dial in 10 minutes prior to the start of the call.

For those unable to participate in the conference call, a replay will be available for two weeks beginning on August 13, 2025 through August 27, 2025. To access the replay, the dial-in number is 877-481-4010 and 919-882-2331. The replay passcode is 52770.

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
jroy@electrovaya.com / 905-855-4618

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries without compromising energy and power. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries, battery systems, and battery-related products for energy storage, clean electric transportation, and other specialized applications. Electrovaya has two operating sites in Canada and a 52-acre site with a 135,000 square foot manufacturing facility in Jamestown New York state for its planned gigafactory. To learn more about how Electrovaya is powering mobility and energy storage, please explore www.electrovaya.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements that relate to, among other things, revenue growth and revenue guidance of approximately $60 million in FY 2025, other financial projections, including projected sales, cost of sales, gross margin, working capital, cash flow, and overheads anticipated in FY 2025, the expected timing of deliveries of pre-production battery modules in Japan, anticipated cash needs and the Company’s requirements for additional financing, purchase orders, mass production schedules, funding from EXIM and the ability to satisfy the conditions to drawing on any facility entered into with EXIM,, use of proceeds of the EXIM facility,, ability to deliver to customer requirements. Forward-looking statements can generally, but not always, be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors and assumptions are applied in making forward looking statements, and actual results may differ materially from those expressed or implied in such statements. In making the forward-looking statements included in this news release, the Company has made various material assumptions, including but not limited to assumptions with respect to the Company’s customers deploying its products in accordance with communicated intentions, the Company’s customers completing new distribution centres in accordance with communicated expectations, intentions and plans, anticipated new orders in FY 2025 based on customers’ historical patterns and additional demand communicated to the Company and its partners, but not yet provided as a purchase order together with the Company’s current firm purchase order backlog totaling approximately $80 million, a discount of approximately 25% used in the revenue modeling applied to the overall expected order pipeline to account for potential delays in customer orders, expected decreases in input and material costs combined with stable selling prices in FY 2025, delivery of ordered products on a basis consistent with past deliveries, and that the Company’s customer counterparties will meet their production and demand growth targets, ]the Company’s ability to successfully execute its plans and intentions, including with respect to the entry into new business segments and servicing existing customers, the availability to obtain financing on reasonable commercial terms, including any EXIM facility. Factors that could cause actual results to differ materially from expectations include but are not limited to customers not placing orders roughly in accordance with historical ordering patterns and communicated intentions, macroeconomic effects on the Company and its business, and on the lithium battery industry generally, not being able to obtain financing on reasonable commercial terms or at all, including not being able to satisfy any condition of drawdowns under any EXIM facility if entered into, that the Company’s products will not perform as expected, supply and demand fundamentals for lithium-ion batteries, the risk of interest rate increases, persistent inflation in the United States and Canada and other macroeconomic challenges, the political, economic, and regulatory and business stability of, or otherwise affecting, the jurisdictions in which the Company operates, including new tariff regimes. There have been indications from the United States government of potential tariffs on Canada, Mexico and other countries, which if enacted would have a material impact on the Company. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s Annual Information Form for the year ended September 30, 2024 under “Risk Factors”, and in the Company’s most recent annual and interim Management’s Discussion and Analysis under “Qualitative And Quantitative Disclosures about Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities and filed or furnished with the SEC. The Company does not undertake any obligation to update publicly or to revise any of the forward looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

Revenue guidance for FY2025 described herein constitutes future‐oriented financial information and financial outlooks (collectively, “FOFI“), and generally, is, without limitation, based on the assumptions and subject to the risks set out above under “Forward‐Looking Statements”. Although management believes such assumptions to be reasonable, a number of such assumptions are beyond the Company’s control and there can be no assurance that the assumptions made in preparing the FOFI will prove accurate. FOFI is provided for the purpose of providing information about management’s current expectations and plans relating to the Company’s future performance, and may not be appropriate for other purposes.

The FOFI does not purport to present the Company’s financial condition in accordance with IFRS, and it is expected that there may be differences between audited results and preliminary results, and the differences may be material. The inclusion of the FOFI in this news release disclosure should not be regarded as an indication that the Company considers the FOFI to be a reliable prediction of future events, and the FOFI should not be relied upon as such.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

ARLINGTON, VA / ACCESS Newswire / August 13, 2025 / FriskaAi announced today an agreement with DexCom, Inc., the global leader in glucose biosensing, to integrate data from Dexcom G7 and Dexcom G6 Continuous Glucose Monitoring (CGM) Systems into the FriskaAi platform. Under the agreement, data from Dexcom CGMs will be integrated with Friska Ai, the company’s groundbreaking AI-powered healthcare platform supporting physicians and patients with actionable personalized care management programs.

FriskaAi is a physician-directed health and wellness platform that supports the management of diabetes and other chronic diseases by helping providers take an evidence-based approach to preventive care. The EHR-agnostic FriskaAi platform leverages advanced AI and mobile technology to generate personalized health insights and recommendations, empowering patients to take control of their health journey in partnership with their clinical team.

“Impacting more than 38 million Americans, diabetes has emerged as a major public health problem, and its effective management has become a foundational element of preventive medicine,” says Shaji Nair, CEO of FriskaAi. “Dexcom’s pioneering CGMs are vital tools not only for diabetes management but also for informing broader care decisions. FriskaAi is excited about the potential this integration with Dexcom presents to the physicians relying on our platform for chronic disease management and the patients seeking greater control over their health and wellness.”

Dexcom CGMs use a small, wearable sensor to continuously measure and send glucose levels wirelessly to a smart device or receiver in real-time, without the need for fingerpricks. Dexcom CGMs also offer a suite of customizable alerts that can warn of high or low glucose levels and send predictive alerts to help users spend more time in range.

The FriskaAi mobile app securely integrates with Dexcom CGMs and other smart devices, as well as health apps, for analysis by the powerful HIPAA-compliant FriskaAi platform. That data, along with other clinical data and studies, is continuously monitored by sophisticated AI-powered algorithms that alert the patient when action is recommended and generate actionable reports for use by the clinician at the point of care to inform care decisions.

Aggregated health data is also analyzed within the FriskaAI platform to help physicians identify trends and risks within their patient populations, enabling more proactive and preventive care strategies.

About FriskaAi

FriskaAi is a powerful AI-enabled EHR-agnostic platform that helps physicians and other providers take an evidence-based approach to preventive care. The physician-initiated platform leverages advanced AI- and mobile technology to provide patients with personalized health insights and recommendations, empowering them to take control of their health journey in partnership with their clinical team. This aggregated health data, including information from patients’ glucometers, other smart devices, and health apps, is continuously analyzed by advanced evidence-based algorithms that alert the patient when action is needed and provide clinicians with actionable reports to inform care decisions. FriskaAi also supports population health strategies by analyzing aggregated health data to identify trends and risks within a defined patient population. For more information, visit www.friska.ai.

Media Contact:
Michele Nachum
NPC Creative Services
michele@npccs.com

SOURCE: FriskaAi

View the original press release on ACCESS Newswire

BROOKLYN, NY / ACCESS Newswire / August 13, 2025 / IEH Corporation (OTC:IEHC) yesterday filed with the Securities and Exchange Commission (SEC) its quarterly report on Form 10-Q for the 1^st fiscal quarter ended June 30, 2025.

Highlights include:

• 11% Decrease in Revenue as compared to first quarter of Fiscal Year 2025

• $755,306 loss in Operating Income

• Cash 43% higher than first quarter of Fiscal Year 2025

• Backlog increase of 25% since beginning of Fiscal Year 2026

• Over $2.5 million in orders supporting missile defense programs booked in recent weeks

For the quarter ended June 30, 2025, IEH had revenues of $6,308,155 as compared to $7,104,977 for the quarter ended June 30, 2024 reflecting an 11% decrease; an operating loss of $755,306 for 1^st quarter fiscal year 2026 as compared to an operating gain of $332,979 for 1^st quarter fiscal year 2025; a net loss of $654,618 for 1^st quarter fiscal year 2026 as compared to a net gain of $392,787 for 1^st quarter fiscal year 2025; and a basic loss per share of $.27 for 1^st quarter fiscal year 2026 as compared to a basic gain per share of $.17 for 1^st quarter fiscal year 2025.

Dave Offerman, President and CEO of IEH Corporation commented, “As forecasted in prior communications, while our long-term trajectory continues to trend upwards, our results from one quarter to the next may be uneven. This is reflected in our first quarter, as revenue was lower than the last few quarters due primarily to customer schedule delays, along with the still slow recovery of the commercial aircraft sector.

However, the long-term projections, especially in our largest sector, defense, remain strong. Indeed, we recently booked over $2.5 million in orders in support of various missile defense programs, including PATRIOT, AMRAAM, LTMADS and others. Our sales pipeline indicates more orders are on the horizon. Our commercial space launch business continues to grow, and we continue to eagerly anticipate a return to pre-COVID levels of business in the commercial aerospace sector. Initiatives to grow our product lines and markets served via organic and inorganic growth continue, and we look forward to sharing more good news in the coming quarters.

On behalf of the management team and staff of IEH, we again wish to express our sincere gratitude for the support of our valued shareholders.”

About IEH Corporation

For over 80 years and 4 generations of family-run management, IEH Corporation has designed, developed, and manufactured printed circuit board (PCB) connectors, custom interconnects and contacts for high performance applications. With its signature Hyperboloid technology, IEH supplies the most durable, reliable connectors for the most demanding environments. The Company markets primarily to companies in defense, aerospace, medical, space and industrial applications, in the United States, Canada, Europe, Southeast and Central Asia and the Mideast. The Company was founded in 1941 and is headquartered in Brooklyn, New York.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this press release, and in related comments by the Company’s management, include “forward-looking statements.” All statements, other than statements of historical facts, including, without limitation, statements or expectations regarding our financial condition, statements or expectations regarding our revenues, cash and backlog, expectations regarding future cash requirements, revenue and revenue recovery, including for fiscal year 2026 and beyond, projected timelines for making our SEC filings or successfully preventing our registration from suspension or revocation and expectations regarding our efforts and ability to resolve our inventory accounting issues are forward-looking statements. These statements often include words such as “believe,” “expect,” “estimate,” “plan,” “will,” “may,” “would,” “should,” “could,” or similar expressions, although not all forward-looking statements contain such identifying words. These statements are based on certain assumptions that the Company has made on its current expectations and projections about future events. The Company believes these judgments are reasonable, but you should understand that these statements are not guarantees of performance or results, and you should not place undue reliance on any forward-looking statements. The Company’s actual performance or results could differ materially from those expressed in the forward-looking statements due to a variety of important factors, both positive and negative, as they will depend on many factors about which we are unsure, including many factors beyond our control. Among other items, such factors could include: any claims, investigations or proceedings arising as a result of our past due periodic reports, including changes in the proceedings related to the SEC’s Order Instituting Administrative Proceedings and Notice of Hearing pursuant to Section 12(j) of the Securities and Exchange Act of 1934, as amended; our ability to remediate our inventory accounting issue; our ability to reduce costs or increase revenue; changes in the macroeconomic environment or in the finances of our customers; changes in accounting principles, or their application or interpretation, and our ability to make accurate estimates and the assumptions underlying the estimates; our ability to attract and retain key employees and key resources; and other risk factors discussed from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on June 12, 2025, and in subsequent reports filed with or furnished to the SEC. Additional information concerning these and other factors can be found in our filings with the SEC. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. Except as may be required by applicable law, we do not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking statements contained in this press release as a result of new information or future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should carefully review and consider the various disclosures we make in our filings with the SEC that attempt to advise interested parties of the risks, uncertainties and other factors that may affect our business.

Contact:

Dave Offerman
IEH Corporation
dave@iehcorp.com
718-492-4448

SOURCE: IEH Corp.

View the original press release on ACCESS Newswire

• XCF Global and OpenSponsorship partner to provide sports, entertainment, and music industries with carbon-neutral air travel opportunities

• Initiative drives awareness around reducing aviation emissions by offering a practical carbon offset solution

• Partnership empowers athletes, entertainers, and musicians to leverage their platforms to promote positive societal change

HOUSTON, TEXAS / ACCESS Newswire / August 13, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Synthetic Aviation Fuel (“SAF”) today announces a strategic partnership with OpenSponsorship Corp. (“OpenSponsorship”), a New York-based marketing agency specializing in sponsorships for sports and entertainment industries to drive awareness for carbon-neutral air travel. This campaign creates unique opportunities for sports teams, actors and actresses, and musicians to participate in carbon-neutral travel activities, raising awareness around the decarbonization of air travel.

As part of the partnership, XCF will offer a comprehensive carbon offset solution for sports and entertainment travel, ensuring that flights to games,tournaments, concerts, and other events are fully carbon neutral. Such sponsorships aim to demonstrate a practical and impactful approach to sustainability, contributing to the global movement toward reducing emissions from the aviation industry.

Mihir Dange, CEO and Board Chair of XCF Global commented:

“We are thrilled to partner with OpenSponsorship and bring carbon-neutral travel opportunities to sports, entertainment, and music industries. This partnership enables high-profile individuals and organizations to meaningfully engage with their audiences by showcasing their leadership in sustainability and driving awareness of the need to decarbonize the aviation industry. Together, we’re turning the spotlight on the urgent need to decarbonize the aviation industry and providing a clear path for others to follow.”

OpenSponsorship is revolutionizing the sponsorship landscape by simplifying the connection between brands and talent in the sports, entertainment, and music industries. Their platform provides brands of all industries with streamlined access to the benefits of sports and entertainment sponsorships, empowering them to engage with talent and athletes through mutually beneficial partnerships.

OpenSponsorship Founder and CEO, Ishveen Jolly said:

“We’re excited to work with XCF to bring carbon-neutral travel to the forefront of sports and entertainment sponsorships. Athletes, musicians, and actors hold immense influence, and their global followings make them powerful advocates for change. This partnership empowers them to lead by example, using their platforms to inspire fans and effect positive societal change.”

To explore exciting partnership opportunities or discuss customized sponsorships, reach out to OpenSponsorship at info@opensponsorship.com or visit https://opensponsorship.com/.

About XCF Global, Inc.

XCF Global, Inc. is a pioneering synthetic aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~149.3 million; 20% free float (as of August 13, 2025).

To learn more, visit www.xcf.global.

Contacts

XCF Global:
C/O Camarco
XCFGlobal@camarco.co.uk

Media:

Camarco
Andrew Archer | Rosie Driscoll | Violet Wilson
XCFGlobal@camarco.co.uk

Forward Looking Statements

This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses resulting from potential inflationary pressures and rising interest rates, including manufacturing and operating expenses and interest expenses; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing in the future and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (11) costs related to the Business Combination and the New Rise acquisitions; (12) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (13) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) changes in applicable laws or regulations; (15) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (16) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (17) the availability of tax credits and other federal, state or local government support; (18) risks relating to XCF Global’s and New Rise’s key intellectual property rights; (19) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (20) the effects of increased costs associated with operating as a public company; and (21) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global makes with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

SOURCE: XCF Global, Inc.

View the original press release on ACCESS Newswire

RED BANK, NEW JERSEY / ACCESS Newswire / August 13, 2025 / Tharimmune, Inc. (Nasdaq:THAR) (“Tharimmune” or the “Company”), a clinical-stage biotechnology company dedicated to developing innovative therapeutic candidates for inflammation, immunology, and critical unmet medical needs, today announced a significant expansion of its intellectual property portfolio for TH-104, its novel transmucosal film. The new patents, recently granted and allowed across key global markets, will enable the Company’s long-term strategy of pursuing broader indications for the technology, beginning with its lead program as a critical medical countermeasure for military and first responders against high-potency opioids.

This announcement follows recent positive feedback from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) pathway for TH-104. The FDA confirmed that a 505(b)(2) NDA submission for the prevention of respiratory and/or central nervous system distress is a viable path, and no additional clinical trials seem to be required for this specific indication for use in military personnel and/or first responders who may be exposed to weaponized high-potency opioids, such as fentanyl or its analogues. This positive feedback, combined with the appointment of counter-terrorism expert James Liddy to the Board of Directors, accelerates the Company’s efforts to position TH-104 as a national security solution.

The recent granting and allowance of patents in Japan, Mexico, Australia, and the United States further strengthen the Company’s intellectual property position, providing protection for TH-104 out to at least 2040 in key markets. While the initial focus is on military and first responders, these patents are foundational for addressing other significant medical needs to combat pruritus, a debilitating form of itch associated with certain chronic liver and kidney diseases.

TH-104 is a buccal film formulation of nalmefene, an opioid antagonist with a significantly longer half-life compared to existing options of autoinjectors and other formulations containing the active ingredient of products such as Narcan^®. This extended duration may provide sustained protection, which is crucial for personnel operating in high-risk environments where repeated dosing may not be feasible.

“The recent patent grants are important for our TH-104 platform,” said Sireesh Appajosyula, CEO of Tharimmune. “This is a dual achievement which validates our innovative drug delivery technology and secures the long-term potential of TH-104 to address multiple high-impact indications. While we are prioritizing its role as a life-saving medical countermeasure for our military and first responders, this patent portfolio provides a runway to develop our lead candidate for other debilitating conditions where there is a significant unmet medical need.”

The newly granted and allowed patents specifically cover a novel method and device for transmucosal administration of nalmefene via a single-layer, self-supporting, mucoadhesive film with distinct domains for optimized drug delivery and pH balance.

The granted and allowed patents include:

• United States (US) Application No. 17/285,971 (Allowed)

• Japan (JP) Patent No. 7603583 (Granted)

• Mexico (MX) Patent No. 422769 (Granted)

• Australia (AU) Patent Application No. 2019361980 (Allowed)

Tharimmune is dedicated to advancing TH-104 to provide a potentially effective and patient-friendly treatment as an option for those in need, beginning with its critical role in national security.

About Tharimmune, Inc.

Tharimmune is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter environments contaminated with high-potency opioids. The expanded pipeline includes other indications for TH104, such as chronic pruritus in primary biliary cholangitis and TH023, a new approach to treating autoimmune diseases along with an early-stage multispecific biologic platform targeting unique epitopes against multiple solid tumors through its proprietary EpiClick^™ Technology. The Company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. Tharimmune continues to position itself as a leader in patient-centered innovation while working to deliver long-term value for shareholders. For more information, visit: www.tharimmune.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, contained in this press release, including statements regarding the timing and design of Tharimmune’s future Phase 2 trial, Tharimmune’s strategy, future operations, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. Factors that may cause such differences, include, but are not limited to, those discussed under Risk Factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and other periodic reports filed by the Company from time to time with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date of this release. Subsequent events and developments may cause the Company’s views to change; however, the Company does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this release.

Contacts:

Tharimmune, Inc.
ir@tharimmune.com

SOURCE: Tharimmune Inc.

View the original press release on ACCESS Newswire

Industry experts warn that payroll mistakes are becoming a leading cause of tax penalties for small business owners in 2025.

IRVINE, CALIFORNIA / ACCESS Newswire / August 13, 2025 / A growing number of small business owners are facing costly penalties from the Internal Revenue Service (IRS) due to payroll errors, according to recent industry data. With changing regulations, new digital filing requirements, and heightened IRS enforcement, experts say payroll missteps are more than just bookkeeping blunders – they can become expensive liabilities.

“Payroll isn’t just about paying employees on time – it’s about paying the right taxes, to the right agencies, at the right time,” said a spokesperson for Clear Start Tax, a national tax relief and resolution firm. “We’re seeing an uptick in IRS penalties for businesses that underreport, misclassify employees, or miss deposit deadlines, and the financial fallout can be devastating.”

Common mistakes include misclassifying workers as independent contractors instead of employees, failing to deposit withheld taxes promptly, and overlooking quarterly filing requirements. These errors can lead to penalties, interest charges, and in some cases, IRS liens or levies.

Clear Start Tax warns that the IRS has increased its use of automated systems to flag payroll inconsistencies.

“Business owners need to understand that payroll taxes are one of the IRS’s top collection priorities,” the spokesperson added. “Once a payroll issue is identified, the clock starts ticking, and penalties can snowball quickly.”

To help business owners stay compliant, Clear Start Tax recommends:

• Double-checking worker classification to ensure IRS guidelines are met.

• Scheduling automated tax deposits to avoid missed deadlines.

• Reconciling payroll reports with tax filings each quarter.

• Consulting a tax professional before making major payroll changes.

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

“Proactive compliance is the best defense,” said the spokesperson. “A small oversight today can turn into a major problem six months from now. The businesses that survive and thrive are the ones that get ahead of these issues before the IRS gets involved.”

About Clear Start Tax
Clear Start Tax is a nationwide tax resolution and relief firm specializing in helping individuals and businesses address IRS and state tax issues. With a team of experienced tax professionals, the company provides tailored strategies for resolving back taxes, negotiating settlements, and achieving long-term compliance.

Need Help With Back Taxes?

Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information

Clear Start Tax
Corporate Communications Department
tech@clearstarttax.com
(949) 800-4011

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

• BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential

• 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees

• Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™’s four bold flavors

• As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake

• BUZZ BOMB™ is available for purchase at buzzbomb.buzz, the Company’s new E-commerce website

ESTERO, FL / ACCESS Newswire / August 13, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending supplement delivery technology, today announced the successful launch and distribution of over 30,000 BUZZ BOMB™ sample four-packs, its newsublingual pre-workout supplement, at FitCon and FitExpo, held August 1-3, in Salt Lake City and Anaheim, with an estimated combined attendance in excess of 70,000 people.

BUZZ BOMB™, featuring 50mg of caffeine and offered in four flavors (Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha), provides nearly instant energy, in easy-to-use small sublingual packets, which can be taken right before and during work out as needed. Unlike most pre-workout products that are mixed with water and taken well before a workout, BUZZ BOMB™ is sprinkled under the tongue right before or during a workout for immediate effect via direct delivery to the bloodstream.

BUZZ BOMB™ FitExpo Launch

Click here for BUZZ BOMB FitExpo Convention August 2-3, 2025 Video

BUZZ BOMB™ Testimonial from Leading Figures in the Fitness World

Bobby Maximus is a UFC fighter, Ju Jitsu Masters World Champion and fitness trainer. He has broken multiple power-endurance world records and is recognized as a leading figure in the fitness world. He starred in the recent feature film “Kill Shot” and is a best-selling Men’s Health author and a regular contributor to “Men’s Health” magazine (https://www.menshealth.com/author/214988/bobby-maximus/).

“In just about a minute, it feels like I drank a pre-workout 20 minutes ago.”

“The taste… phenomenal! I really like that.”

“I work out 2-3 times a day. One of the most inconvenient things is trying to time your pre workout drink 30 minutes before your workout. “

When I have a short window, I don’t want to wait 30 minutes until it kicks in. The ability to just ‘dump and go’ with Buzz Bomb, is powerful. It’s the convenience factor!

“I love the idea behind it! It helps me keep my caffeine intake down. Especially when you train 2 to 3 times a day.”

“You cannot find another pre work with 50 mgs of caffeine… and it works! I love it!”

Brandon “MidWest Kong” Copeland (pictured above, third to the right) embodies the strength of a champion and the heart of a hero. A Brazilian Jiu-jitsu Black Belt, Copeland dominated the Mixed Martial Arts scene from 2005 to 2014, showcasing tenacity and skill. Initiating the “I Stopped The Bully” campaign in 2011, he became a beacon against bullying, inspiring youth across schools and detention centers. Copeland excelled in the fitness industry, breaking records like bench pressing 225 pounds 81 consecutive times. A published children’s book author, he spreads messages of hope and community.

“I took the product! Let me say thank God! No heart flutter, no itchy sensation, no crash! I don’t need the hard stuff anymore…feels absolutely great! I had a great workout as well!”

Commenting on the BUZZ BOMB™ launch, Kraig Higginson, Interim Chief Executive Officer of Aspire, said, “The launch and consumer response to BUZZ BOMB™ at two of the major fitness conventions, from booth activity, product sampling, feedback, interest from fitness experts and influencers, and potential licensing partners, exceeded all of our high expectations.”

Higginson added, “With BUZZ BOMB™, we’re raising the bar for ease of use, performance and value in the multi-billion-dollar caffeine category. We focused on creating a formula that is fast-absorbing and built for athletes, fitness enthusiasts and consumers who demand clean, effective fuel without unnecessary fillers or compromise. With online sales commencing August 1, we are now focused on increasing our marketing, expanding our third-party manufacturing capabilities, and preparing for further discussions with potential licensing partners in the nutritional and supplement space that can help us drive increased consumer awareness and accelerate our revenue potential for BUZZ BOMB™.”

Consumers can purchase BUZZ BOMB™ online at buzzbomb.buzz

BUZZ BOMB™ Pre-workout Benefits:

• Speed – works nearly immediately (less than 2 minutes) vs. 20-30 minutes

• Convenience – easy to use single-use packets vs. mixing and measuring for beverages

• Energy management – use as needed to precisely manage caffeine intake (50mg increments)

• Single Safe Active Ingredient – well-known benefits and use of caffeine

• A clean manageable Energy Boost

• Low manufacturing & packaging costs – competitive pricing with high margin potential

Aspire’s BUZZ BOMB™ – Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market.

About Aspire Biopharma, Inc.

Headquartered in Estero, Fl., Aspire Biopharma has developed a patent-pending disruptive technology that can deliver supplements and drugs to the body rapidly and precisely with less negative impact to the system by going directly to the bloodstream and avoiding the gastrointestinal tract. For more information, please visit www.aspirebiolabs.com.

Safe Harbor Statement

Certain statements made in this communication are “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may generally be identified by the use of words such as “estimate,” “projects,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “would,” “should,” “future,” “propose,” “potential,” “target,” “goal,” “objective,” “outlook” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding the financial position, business strategy and the plans and objectives of management for future operations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Aspire’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the parties, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Aspire Biopharma Holdings, Inc.

Contact

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Rene Veloso, JD, MBA, joins KIFFIK to lead investor relations and secure new funding to fuel clinical operations

Rubix Life Sciences CEO Reginald Swift, Ph.D. joins as Chief Scientific Officer with responsibility to shape KIFFIK’s clinical strategy

PROVIDENCE, RI / ACCESS Newswire / August 13, 2025 / KIFFIK Biomedical, Inc. (“Kiffik”), a leader in interstitial fluid (ISF)-based diagnostics, today announced two new appointments to its leadership team. Healthcare development executive Rene Veloso joins as Chief Investment Officer (CIO) along with Dr. Reginald(Reggie) Swift who will serve as a fractional Chief Scientific Officer (CSO).

“The addition of Rene and Reggie to our already strong leadership team is a game-changer as we embark on our next chapter of growth,” said George Cagna, CEO of KIFFIK Biomedical. “Ensuring our R&D function is meeting the highest scientific standards, coupled with securing operating capital, empowers our team to bring next-generation ISF biomonitoring to partners and patients.”

As CIO, Rene will be responsible for securing capital investments from institutional partners that want to unlock the full potential of interstitial fluid real-time monitoring for a range of cancers and other diseases. Most recently, Rene was Senior Vice President at Locust Walk Partners, LLC where he led multiple high-profile M&A activities on behalf of biopharma clients.

Dr. Reginald Swift is the CEO of Rubix Life Sciences, a leader in aptamer-based precision medicine. As a fractional CSO for KIFFIK Dr. Swift will help shape clinical operations to ensure research and development activities meet the highest scientific standards. Earlier this year, KIFFIK and Rubix LS established a strategic partnership to advance next-generation ISF extraction technology.

About KIFFIK Biomedical

KIFFIK Biomedical is pioneering interstitial fluid (ISF)-based diagnostics, transforming disease detection and health monitoring with a needle-free, real-time approach. As a leader in ISF science and biomarker detection, we are redefining non-invasive diagnostics for oncology, therapeutic monitoring, and beyond.

Our proprietary and patented KIFFIK EXP platform unlocks the potential of ISF, providing high-precision, accessible, and patient-friendly solutions. Through strategic partnerships and cutting-edge research, KIFFIK is driving the future of precision medicine and advancing diagnostics that empower earlier detection and better health outcomes.

###

Media Contact

MDL Strategic Communications
Michael Lauer
michael@mdlcomms.com

SOURCE: Kiffik

View the original press release on ACCESS Newswire

BARRIE, ON / ACCESS Newswire / August 13, 2025 / Abrams Towing, a trusted provider of professional towing services in Southern Ontario, has been named a 2025 Consumer Choice Award recipient in the category of Towing Services for the Barrie region. This recognition reflects Abrams’ longstanding commitment to safe, efficient, and dependable roadside assistance-backed by more than 40 years of industry experience.

With a reputation for fast response times and professional service, Abrams has grown from a one-man operation into Canada’s largest towing company. Today, the company provides 24/7 towing and roadside assistance to individuals, businesses, municipalities, and emergency services across key regions, including Barrie, Newmarket, Toronto, Mississauga, Ottawa, Durham Region, Oakville, Hamilton, London, Cambridge and Windsor.

Over Four Decades of Trusted Towing Experience

Abrams Towing has built its operations around reliability, expertise, and customer care. With a fleet of more than 160 state-of-the-art tow trucks and a team of certified operators, the company handles a wide range of towing and recovery needs-from light-duty and flatbed towing to heavy-duty recovery, accident cleanup, and winching.

“Our team understands that breakdowns and accidents are stressful,” says the Abrams Towing team. “That’s why we’ve built a model focused on responsiveness, safety, and customer care-no matter the size or scope of the job.”

24/7 Towing Services Across Southern Ontario

Abrams operates a 24/7 live dispatch system, ensuring timely service around the clock. With operators strategically located throughout Ontario, including in Barrie, the company is well-positioned to respond quickly in both urban and rural areas.

Abrams offers a comprehensive suite of services, including:

• Private Property Towing

• 24/7 Emergency Towing

• Long Distance Towing

• Roadside Assistance

• Lockouts

• Boosts

• Fuel Delivery

• Tire Changes

• Specialty Towing / Equipment Winching

• Commercial Towing

Drivers arrive fully equipped to manage most issues on-site, helping minimize downtime and stress for customers.

“We take pride in being there for our customers when they need us most,” the team adds. “Whether someone is stranded on the highway or a commercial client needs reliable support, our priority is to respond quickly and professionally.”

Committed to Safety and Innovation
Abrams places a strong emphasis on safety and operator training. All vehicles are equipped with GPS tracking, emergency lighting, and modern safety features to ensure compliant and secure towing. Operators follow strict safety protocols and receive ongoing education to stay aligned with industry standards.

To support long-term growth and environmental goals, Abrams has also invested in fleet upgrades and efficiency measures that reduce emissions and improve service delivery.

Serving Barrie and the Greater Region
While Abrams has a large presence throughout Ontario, local teams-like the one in Barrie-are essential to delivering personalized, community-focused service. Their knowledge of local roads, traffic conditions, and regional infrastructure allows them to provide fast, effective support tailored to each area’s needs.

“This recognition reinforces the commitment we’ve made to every driver, fleet manager, and emergency responder we work with,” says the Abrams Towing team. “We’re honoured to serve the Barrie community and proud to be part of a network that prioritizes safety, speed, and service excellence.”

Recognition Backed by Independent Research
The Consumer Choice Award is the only organization in North America that recognizes business excellence through a four-step, independent research process. This includes third-party surveys, consumer feedback analysis, and brand reputation evaluation within each local market.

Being named a Consumer Choice Award recipient means Abrams Towing has earned high marks for customer satisfaction and service quality from the people who matter most-their customers.

To learn more about Abrams’ services, CLICK HERE or visit www.abrams.ca.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

WATERLOO, ON / ACCESS Newswire / August 13, 2025 / Mitchell Blackwell Parging & Masonry Inc., a family-run masonry specialist known for quality craftsmanship, has won the 2026 Consumer Choice Award in the Masonry category for the Waterloo Region. This award recognizes Mitchell Blackwell Parging & Masonry Inc.’s 11 years of service-building on a family legacy that spans nearly four decades-with a focus on quality, reliability, and exceptional value.

Established in 2014 by Mitchell Blackwell-and building on two generations of skilled bricklayers-the company has become a trusted name in Kitchener-Waterloo and surrounding areas. Their diverse portfolio ranges from foundation repair and parging finishes to chimney restoration, stone patios, tuckpointing, epoxy flooring, and decorative concrete work.

“Our foundation is built on family values,” says Mitchell Blackwell, founder. “With nearly four decades of combined experience, we approach every project-whether parging a foundation or restoring heritage brick-with precision, respect, and pride.”

Comprehensive Masonry & Parging Solutions
Mitchell Blackwell Parging & Masonry offers a wide range of services designed to meet both aesthetic and structural needs:

• Parging & Foundation Repair – Sand‑face, stone‑face, and custom finishes designed to enhance and protect foundations.

• Brickwork & Stone Construction – Chimney and fireplace restoration, retaining walls, veneer stone, custom patio features, heritage brick repair, and tuckpointing.

• Concrete & Epoxy Finishes – Durable coatings for garages, basements, and commercial spaces, including polishing, staining, and crack repair.

Their experienced teams ensure workmanship that stands the test of time and looks exceptional too.

Trusted Experience and Community Recognition
Mitchell learned the trade from his father and, since 2014, has applied that family craftsmanship across hundreds of projects in Waterloo, Cambridge, Kitchener, and beyond. The company consistently delivers projects on time and within budget, earning praise for both skill and client service.

Customer testimonials reflect satisfaction in quality, punctuality, cleanliness, and professionalism-particularly on tight schedules and complex work.

Reliable Results with a Personal Touch
Mitchell Blackwell Parging & Masonry balances industrial-grade results with a personal, family-driven touch. Regardless of project size, their goal remains the same: to execute with care, communicate clearly, and make each customer feel respected.

They serve both residential and commercial clients, ensuring that materials, ornamental details, and structural improvements align with the client’s vision and the property’s needs.

Commitment That Builds Trust
Winning the Consumer Choice Award reflects the trust that homeowners and businesses across Waterloo Region have placed in Mitchell Blackwell Parging & Masonry Inc. This recognition reinforces the company’s dedication to quality, reliability, and craftsmanship in every project they undertake.

“This award validates our dedication to quality and community,” says Mitchell. “We’re grateful for the trust our clients show us-and we’re committed to building stronger foundations for the region.”

About Mitchell Blackwell Parging & Masonry Inc.
Coming from a bricklaying family, Mitchell is hands-on in every project, and his crew of skilled tradespeople reflects that same passion and expertise. Their gallery of past work includes foundations, chimneys, patios, and epoxy floors that showcase both functionality and aesthetic appeal.

To request a quote or learn more about services, visit mitchellblackwellparging.com or their CCA Page.

About Consumer Choice Award:
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category earn this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information:
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire